Evommune’s EVO756 Performs Well in Phase 2 Study of Adults With CIndU
Fully 30% of adult chronic inducible urticaria (CIndU) patients achieved a complete response after four weeks of dosing with EVO756, a potent, highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2).